Browse Tag

Georgian distribution company Orbita

Gilead and Novo Nordisk announced new data from proof-of-concept trial in NASH

4 mins read

The FINANCIAL — Gilead Sciences, Inc. and Novo Nordisk A/S announced results from a phase 2 proof-of-concept trial. The five-arm trial evaluated combinations of Novo Nordisk’s semaglutide, a GLP-1 receptor agonist, with Gilead’s investigational FXR agonist cilofexor and/or Gilead’s investigational ACC inhibitor firsocostat over 24 weeks in 108 people with non-alcoholic steatohepatitis (NASH). The results were presented at The Liver Meeting Digital Experience (TLMdX), 13–16 November 2020 (Late Breaker #L02). The trial met its primary endpoint by demonstrating that in people with NASH and mild to moderate fibrosis all regimens were well tolerated. The most common adverse events (AEs) were…

Read More »

Gilead and Novo Nordisk announced new data from proof-of-concept trial in NASH

4 mins read

The FINANCIAL — Gilead Sciences, Inc. and Novo Nordisk A/S announced results from a phase 2 proof-of-concept trial. The five-arm trial evaluated combinations of Novo Nordisk’s semaglutide, a GLP-1 receptor agonist, with Gilead’s investigational FXR agonist cilofexor and/or Gilead’s investigational ACC inhibitor firsocostat over 24 weeks in 108 people with non-alcoholic steatohepatitis (NASH). The results…

Orbita to Offer New Assortment of Snacks in 2019

5 mins read

Georgian distribution company Orbita plans to increase its assortment of snacks this year and offer innovative products to the Georgian market by 2020. General Director of Orbita, Giorgi Davitadze, said that the new assortment of snacks will include hazelnuts blended with different spices. Orbita was established in 2004, however the company has been operating on…